iopromide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1468	73334-07-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iopromide iopromidum	Molecular weight: 791.12 Formula: C18H24I3N3O8 CLOGP: -1.67 LIPINSKI: 3 HAC: 11 HDO: 6 TPSA: 168.66 ALOGS: -3.34 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iopromide
iopromidum

Molecular weight: 791.12
Formula: C18H24I3N3O8
CLOGP: -1.67
LIPINSKI: 3
HAC: 11
HDO: 6
TPSA: 168.66
ALOGS: -3.34
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	97 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3227.25 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	2.60 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ
CL (Clearance)	1.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.99 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.22 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
May 10, 1995	FDA	BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	365.62	50.22	179	3345	165623	63319875
Erythema	202.90	50.22	124	3400	175627	63309871
Contrast media reaction	180.42	50.22	34	3490	1091	63484407
Anaphylactic shock	171.18	50.22	60	3464	23573	63461925
Pruritus	162.10	50.22	144	3380	361309	63124189
Contrast media allergy	149.18	50.22	33	3491	2368	63483130
Sneezing	146.40	50.22	50	3474	18168	63467330
Contrast encephalopathy	129.87	50.22	18	3506	70	63485428
Dyspnoea	112.96	50.22	159	3365	661154	62824344
Blood pressure decreased	98.80	50.22	55	3469	64967	63420531

Showing 1 to 10 of 19 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	363.48	48.47	152	2891	62225	34891663
Anaphylactic shock	198.77	48.47	68	2975	15873	34938015
Contrast media reaction	195.43	48.47	38	3005	908	34952980
Contrast encephalopathy	156.20	48.47	22	3021	55	34953833
Pruritus	148.87	48.47	112	2931	141869	34812019
Contrast media allergy	128.87	48.47	24	3019	451	34953437
Erythema	110.87	48.47	78	2965	88702	34865186
Sneezing	104.63	48.47	32	3011	5210	34948678
Alveolar lung disease	88.93	48.47	17	3026	369	34953519
Pulmonary interstitial emphysema syndrome	83.75	48.47	17	3026	507	34953381

Showing 1 to 10 of 19 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	593.93	44.99	293	6280	184908	79552907
Anaphylactic shock	361.81	44.99	129	6444	35867	79701948
Contrast media reaction	351.72	44.99	70	6503	2000	79735815
Contrast encephalopathy	274.38	44.99	40	6533	148	79737667
Erythema	274.21	44.99	190	6383	223100	79514715
Pruritus	271.44	44.99	238	6335	394410	79343405
Contrast media allergy	257.83	44.99	56	6517	2466	79735349
Sneezing	230.04	44.99	79	6494	19604	79718211
Nephropathy toxic	149.24	44.99	58	6515	20361	79717454
Blood pressure decreased	148.99	44.99	96	6477	99370	79638445

Showing 1 to 10 of 34 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	V08AB05	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:37338	contrast media
CHEBI has role	CHEBI:50909	agente nefrotoxico
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000180185	Radiographic Contrast Agent
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.84	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
003739	NDDF
27781	RXNORM
353903006	SNOMEDCT_US
3736	PUBCHEM_CID
395756007	SNOMEDCT_US
4020929	VUID
4020929	VANDF
4907	MMSL
4919	INN_ID
712BAC33MZ	UNII

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-342	INJECTION	240 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-342	INJECTION	240 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-342	INJECTION	240 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-342	INJECTION	240 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-342	INJECTION	240 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-342	INJECTION	240 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-344	INJECTION	300 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-344	INJECTION	300 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-344	INJECTION	300 mg	INTRA-ARTERIAL	NDA	27 sections
Ultravist	HUMAN PRESCRIPTION DRUG LABEL	1	50419-344	INJECTION	300 mg	INTRA-ARTERIAL	NDA	27 sections

Showing 1 to 10 of 28 entries

Previous1 2 3Next